These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 6251721)

  • 21. Vitamin D: the discovery of its metabolites and their therapeutic applications.
    Beale MG; Chan JC; Oldham SB; Deluca HF
    Pediatrics; 1976 May; 57(5):729-41. PubMed ID: 181725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of 1,25(OH)2-vitamin D3 to separate 'types' on renal osteodystrophy.
    Coburn JW; Brickman AS; Sherrard DJ; Singer FR; Wong EG; Baylink DJ; Norman AW
    Proc Eur Dial Transplant Assoc; 1977; 14():442-50. PubMed ID: 600961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rickets and osteomalacia.
    Smith R
    Hum Nutr Clin Nutr; 1982; 36(2):115-33. PubMed ID: 7050029
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of 1,25(OH)2D3 and 24,25(OH)2D3 on experimental rickets.
    Kraft D; Offermann G; Steldinger R; Gawlik D
    Res Commun Chem Pathol Pharmacol; 1979 Dec; 26(3):571-80. PubMed ID: 523788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Highly specific binding of 1,25-dihydroxycholecalciferol in bone cytosol.
    Manolagas SC; Taylor CM; Anderson DC
    J Endocrinol; 1979 Jan; 80(1):35-9. PubMed ID: 429951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Privational and malabsorption metabolic bone disease: plasma vitamin D metabolite concentrations and their relationship to quantitative bone histology.
    Compston JE; Vedi S; Merrett AL; Clemens TL; O'Riordan JL; Woodhead JS
    Metab Bone Dis Relat Res; 1981; 3(3):165-70. PubMed ID: 6897097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of vitamin D on bone in vivo.
    Tam CS; Heersche JN; Jones G; Murray TM; Rasmussen H
    Endocrinology; 1986 Jun; 118(6):2217-24. PubMed ID: 3486118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Demonstration of a lack of change in serum 1 alpha,25-dihydroxyvitamin D in response to parathyroid extract in pseudohypoparathyroidism.
    Lambert PW; Hollis BW; Bell NH; Epstein S
    J Clin Invest; 1980 Oct; 66(4):782-91. PubMed ID: 7419719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adult-onset vitamin D-resistant osteomalacia with the unresponsiveness to parathyroid hormone.
    Fujita T; Nomura M; Okajima S; Furuya H
    J Clin Endocrinol Metab; 1980 May; 50(5):927-31. PubMed ID: 6246136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolism of 1,25-dihydroxyvitamin D3.
    Kumar R
    Physiol Rev; 1984 Apr; 64(2):478-504. PubMed ID: 6324253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute actions of 1,25-dihydroxy-vitamin D3 in normal man: effect on calcium and parathyroid status.
    Llach F; Coburn JW; Brickman AS; Kurokawa K; Norman AW; Canterbury JM; Reiss E
    J Clin Endocrinol Metab; 1977 Jun; 44(6):1054-60. PubMed ID: 194908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radioligand receptor assay for 25-hydroxyvitamin D2/D3 and 1 alpha, 25-dihydroxyvitamin D2/D3.
    Hughes MR; Baylink DJ; Jones PG; Haussler MR
    J Clin Invest; 1976 Jul; 58(1):61-70. PubMed ID: 1084355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
    Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H
    Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of the major vitamin D metabolites upon the resolution of osteomalacia in uremic adult rats.
    Lieuallen WG; Weisbrode SE; Horst RL
    Bone; 1990; 11(4):267-73. PubMed ID: 2242292
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 1,25-dihydroxycholecalciferol in hypophosphataemic osteomalacia presenting in adults.
    Offermann G; Delling G; Haussler MR
    Acta Endocrinol (Copenh); 1978 Jun; 88(2):408-16. PubMed ID: 580838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parenteral 1,25-dihydroxycholecalciferol in hepatic osteomalacia.
    Long RG; Varghese Z; Meinhard EA; Skinner RK; Wills MR; Sherlock S
    Br Med J; 1978 Jan; 1(6105):75-7. PubMed ID: 620204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Recent advances on vitamin D (author's transl)].
    Monnier L; Colette C; Mirouze J
    Diabete Metab; 1980 Jun; 6(2):159-68. PubMed ID: 6997104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study.
    Berl T; Berns AS; Hufer WE; Hammill K; Alfrey AC; Arnaud CD; Schrier RW
    Ann Intern Med; 1978 Jun; 88(6):774-80. PubMed ID: 208439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma 1,25(OH)2D3 and iPTH in transplanted adults with persisting hypophosphataemia.
    Ulmann A; Chkoff N; Garabedian M; Lacour B; Descamps JM; Kreis H; Crosnier J; Funck-Brentano JL
    Proc Eur Dial Transplant Assoc; 1980; 17():467-72. PubMed ID: 7017692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.